- Home
- SEVN vs ALEC Comparison
SEVN vs ALEC Comparison
Compare SEVN & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- ALEC
- Stock Information
- Founded
- SEVN 1986
- ALEC 2013
- Country
- SEVN United States
- ALEC United States
- Employees
- SEVN N/A
- ALEC N/A
- Industry
- SEVN Real Estate Investment Trusts
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEVN Real Estate
- ALEC Health Care
- Exchange
- SEVN Nasdaq
- ALEC Nasdaq
- Market Cap
- SEVN 149.0M
- ALEC 124.0M
- IPO Year
- SEVN N/A
- ALEC 2019
- Fundamental
- Price
- SEVN $9.80
- ALEC $1.50
- Analyst Decision
- SEVN Strong Buy
- ALEC Hold
- Analyst Count
- SEVN 2
- ALEC 9
- Target Price
- SEVN $13.50
- ALEC $3.40
- AVG Volume (30 Days)
- SEVN 62.1K
- ALEC 4.6M
- Earning Date
- SEVN 10-27-2025
- ALEC 11-06-2025
- Dividend Yield
- SEVN 11.32%
- ALEC N/A
- EPS Growth
- SEVN N/A
- ALEC N/A
- EPS
- SEVN 1.04
- ALEC N/A
- Revenue
- SEVN $27,061,000.00
- ALEC $81,130,000.00
- Revenue This Year
- SEVN N/A
- ALEC N/A
- Revenue Next Year
- SEVN N/A
- ALEC $290.64
- P/E Ratio
- SEVN $9.53
- ALEC N/A
- Revenue Growth
- SEVN N/A
- ALEC 46.77
- 52 Week Low
- SEVN $9.84
- ALEC $0.87
- 52 Week High
- SEVN $14.10
- ALEC $6.14
- Technical
- Relative Strength Index (RSI)
- SEVN 38.37
- ALEC 27.08
- Support Level
- SEVN $9.84
- ALEC $1.45
- Resistance Level
- SEVN $10.90
- ALEC $1.60
- Average True Range (ATR)
- SEVN 0.25
- ALEC 0.20
- MACD
- SEVN -0.02
- ALEC -0.20
- Stochastic Oscillator
- SEVN 8.49
- ALEC 8.45
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.